PL2597103T3 - Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec - Google Patents
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludecInfo
- Publication number
- PL2597103T3 PL2597103T3 PL13155712T PL13155712T PL2597103T3 PL 2597103 T3 PL2597103 T3 PL 2597103T3 PL 13155712 T PL13155712 T PL 13155712T PL 13155712 T PL13155712 T PL 13155712T PL 2597103 T3 PL2597103 T3 PL 2597103T3
- Authority
- PL
- Poland
- Prior art keywords
- degludec
- liraglutide
- pharmaceutical compositions
- stable pharmaceutical
- stable
- Prior art date
Links
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 title 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title 1
- 108010019598 Liraglutide Proteins 0.000 title 1
- 108010050259 insulin degludec Proteins 0.000 title 1
- 229960002701 liraglutide Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120880 | 2007-11-16 | ||
| EP13155712.6A EP2597103B1 (en) | 2007-11-16 | 2008-11-14 | Stable pharmaceutical compositions comprising liraglutide and degludec |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2597103T3 true PL2597103T3 (pl) | 2017-04-28 |
Family
ID=40639234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08849536T PL2209800T3 (pl) | 2007-11-16 | 2008-11-14 | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| PL13155712T PL2597103T3 (pl) | 2007-11-16 | 2008-11-14 | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08849536T PL2209800T3 (pl) | 2007-11-16 | 2008-11-14 | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8937042B2 (pl) |
| EP (2) | EP2597103B1 (pl) |
| JP (2) | JP5241849B2 (pl) |
| CN (3) | CN107115523A (pl) |
| BR (1) | BRPI0820535B8 (pl) |
| CA (1) | CA2705821A1 (pl) |
| DK (1) | DK2597103T3 (pl) |
| ES (2) | ES2612736T3 (pl) |
| HU (2) | HUE030383T2 (pl) |
| MX (1) | MX2010005245A (pl) |
| NO (1) | NO2017015I1 (pl) |
| PL (2) | PL2209800T3 (pl) |
| PT (1) | PT2597103T (pl) |
| WO (1) | WO2009063072A2 (pl) |
| ZA (1) | ZA201003019B (pl) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2005012347A2 (en) * | 2003-08-05 | 2005-02-10 | Novo Nordisk A/S | Novel insulin derivatives |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PT1969004E (pt) * | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| ATE482977T1 (de) | 2006-02-27 | 2010-10-15 | Novo Nordisk As | Insulinderivate |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| JP5749155B2 (ja) | 2008-03-18 | 2015-07-15 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化アシル化インスリンアナログ |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| AU2014203421B2 (en) * | 2010-05-19 | 2016-07-07 | Sanofi | Long-acting formulations of insulins |
| AU2012216648C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CN106975074A (zh) * | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| PH12014500137A1 (en) | 2011-07-15 | 2017-08-18 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| FR2984749A1 (fr) * | 2011-12-23 | 2013-06-28 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique |
| BR112014002986A2 (pt) | 2011-08-10 | 2017-06-13 | Adocia | composição sob a forma de uma solução injetável, e formulação de dose única |
| WO2013030160A1 (en) | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) * | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| FR2985429B1 (fr) * | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
| FR2985428B1 (fr) * | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
| WO2013104861A1 (fr) | 2012-01-09 | 2013-07-18 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| FR3001896B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| FR3001895B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| SG11201506888VA (en) | 2013-04-03 | 2015-09-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| PE20161153A1 (es) | 2014-01-20 | 2016-10-27 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| MA41138B1 (fr) | 2014-12-12 | 2023-07-31 | Sanofi Aventis Deutschland | Formulation à rapport fixe d'insuline glargine/lixisenatide |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| CN108431019A (zh) | 2015-10-07 | 2018-08-21 | 阿佩利斯制药有限公司 | 给药方案 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| WO2018055539A1 (en) * | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
| RU2764197C1 (ru) | 2016-09-23 | 2022-01-14 | Ханми Фарм. Ко., Лтд. | Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение |
| US20180169190A1 (en) | 2016-12-16 | 2018-06-21 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| WO2018174668A2 (ko) | 2017-03-23 | 2018-09-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| CN110831544B (zh) | 2017-04-07 | 2022-11-18 | 阿佩利斯制药有限公司 | 长效坎普他汀类似物、其组合物的给药方案及其医药用途 |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| CN110669680A (zh) * | 2019-11-04 | 2020-01-10 | 张少清 | 黑酵母菌的培养方法及从黑酵母菌中提取β葡聚糖的工艺 |
| WO2021105393A1 (en) | 2019-11-29 | 2021-06-03 | Novo Nordisk A/S | Processes for obtaining stable glp-1 compositions |
| WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
| EP4090351A4 (en) * | 2020-01-16 | 2023-09-13 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
| JP2023538871A (ja) * | 2020-08-12 | 2023-09-12 | ティーエックスピー ファーマ エージー | エキセンジン－４ペプチド類似体 |
| WO2022268208A1 (zh) * | 2021-06-25 | 2022-12-29 | 甘李药业股份有限公司 | 含酰化胰岛素的药物组合物 |
| US20250000948A1 (en) | 2021-11-15 | 2025-01-02 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| EP0792290B1 (en) | 1993-09-17 | 2001-08-29 | Novo Nordisk A/S | Acylated insulin |
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US20010041786A1 (en) * | 1995-06-07 | 2001-11-15 | Mark L. Brader | Stabilized acylated insulin formulations |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| AU2610699A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| DE19825447A1 (de) * | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| AU2373400A (en) | 1998-12-22 | 2000-07-12 | Eli Lilly And Company | Shelf-stable formulation of glucagon-like peptide-1 |
| JP2003503356A (ja) | 1999-06-25 | 2003-01-28 | メドトロニック ミニメド インコーポレイテッド | 多剤糖尿病治療 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2002000223A1 (en) | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
| EP1432430A4 (en) * | 2001-08-28 | 2006-05-10 | Lilly Co Eli | PREMIXTURES OF GLP-1 AND BASALINSULIN |
| JP2005508360A (ja) * | 2001-10-19 | 2005-03-31 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１およびインスリンの二相混合物 |
| ATE496064T1 (de) | 2002-05-07 | 2011-02-15 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| WO2005012347A2 (en) | 2003-08-05 | 2005-02-10 | Novo Nordisk A/S | Novel insulin derivatives |
| US20060247167A1 (en) * | 2003-09-01 | 2006-11-02 | Novo Nordisk A/S | Stable formulations of peptides |
| US20060287221A1 (en) * | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| WO2005046716A1 (en) | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
| US7192919B2 (en) * | 2004-01-07 | 2007-03-20 | Stelios Tzannis | Sustained release compositions for delivery of pharmaceutical proteins |
| PT1773878E (pt) | 2004-07-19 | 2015-06-05 | Biocon Ltd | Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos |
| EP1791554A2 (en) | 2004-09-17 | 2007-06-06 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
| EP1814581B1 (en) * | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| PT1969004E (pt) * | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| MX2008014061A (es) | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| DE102006031955A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende |
-
2008
- 2008-11-14 DK DK13155712.6T patent/DK2597103T3/en active
- 2008-11-14 CN CN201611159339.1A patent/CN107115523A/zh active Pending
- 2008-11-14 BR BRPI0820535A patent/BRPI0820535B8/pt active IP Right Grant
- 2008-11-14 US US12/741,923 patent/US8937042B2/en active Active
- 2008-11-14 EP EP13155712.6A patent/EP2597103B1/en active Active
- 2008-11-14 PL PL08849536T patent/PL2209800T3/pl unknown
- 2008-11-14 MX MX2010005245A patent/MX2010005245A/es active IP Right Grant
- 2008-11-14 ES ES13155712.6T patent/ES2612736T3/es active Active
- 2008-11-14 JP JP2010533601A patent/JP5241849B2/ja active Active
- 2008-11-14 PT PT131557126T patent/PT2597103T/pt unknown
- 2008-11-14 WO PCT/EP2008/065601 patent/WO2009063072A2/en not_active Ceased
- 2008-11-14 CN CN201710279962.9A patent/CN107412742B/zh active Active
- 2008-11-14 EP EP08849536.1A patent/EP2209800B1/en active Active
- 2008-11-14 HU HUE13155712A patent/HUE030383T2/en unknown
- 2008-11-14 ES ES08849536T patent/ES2430042T3/es active Active
- 2008-11-14 PL PL13155712T patent/PL2597103T3/pl unknown
- 2008-11-14 CA CA2705821A patent/CA2705821A1/en not_active Abandoned
- 2008-11-14 CN CN200880116227A patent/CN101861333A/zh not_active Withdrawn
-
2010
- 2010-04-30 ZA ZA2010/03019A patent/ZA201003019B/en unknown
-
2012
- 2012-05-29 JP JP2012122502A patent/JP5757530B2/ja active Active
-
2017
- 2017-04-21 NO NO2017015C patent/NO2017015I1/no unknown
- 2017-04-24 HU HUS1700016C patent/HUS1700016I1/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0820535B8 (pt) | 2021-05-25 |
| US8937042B2 (en) | 2015-01-20 |
| CN101861333A (zh) | 2010-10-13 |
| DK2597103T3 (en) | 2017-02-13 |
| JP2011503152A (ja) | 2011-01-27 |
| EP2597103A1 (en) | 2013-05-29 |
| ZA201003019B (en) | 2011-06-29 |
| ES2430042T3 (es) | 2013-11-18 |
| ES2612736T3 (es) | 2017-05-18 |
| BRPI0820535A8 (pt) | 2016-10-18 |
| JP2012229214A (ja) | 2012-11-22 |
| EP2597103B1 (en) | 2016-11-02 |
| EP2209800B1 (en) | 2013-07-24 |
| BRPI0820535B1 (pt) | 2020-09-29 |
| NO2017015I2 (no) | 2017-04-21 |
| HUS1700016I1 (hu) | 2017-05-29 |
| CN107115523A (zh) | 2017-09-01 |
| NO2017015I1 (no) | 2017-04-21 |
| CN107412742A (zh) | 2017-12-01 |
| JP5241849B2 (ja) | 2013-07-17 |
| BRPI0820535A2 (pt) | 2016-06-21 |
| US20110152185A1 (en) | 2011-06-23 |
| WO2009063072A2 (en) | 2009-05-22 |
| JP5757530B2 (ja) | 2015-07-29 |
| PT2597103T (pt) | 2017-02-08 |
| WO2009063072A3 (en) | 2010-01-07 |
| CA2705821A1 (en) | 2009-05-22 |
| PL2209800T3 (pl) | 2013-12-31 |
| EP2209800A2 (en) | 2010-07-28 |
| HUE030383T2 (en) | 2017-05-29 |
| MX2010005245A (es) | 2010-06-01 |
| CN107412742B (zh) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1700016I1 (hu) | Liraglutidot és degludeket tartalmazó stabil gyógyszerészeti készítmények | |
| IL242883B (en) | Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them | |
| IL218016A0 (en) | Pharmaceutical compositions comprising bi-1356 and metformin | |
| SI2178549T1 (sl) | Protimikrobni peptid in pripravki iz njega | |
| EP2056835A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| HUE063083T2 (hu) | Nilotinibet vagy sóját tartalmazó gyógyszerészeti készítmények | |
| EP2001498A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL194176A0 (en) | Pharmaceutical compositions | |
| GB0713625D0 (en) | Pharmaceutical compositions | |
| IL204442A (en) | Inhibitors of atpase-0fif, medicinal preparations containing them and their use | |
| IL200885A (en) | A history of mannich-based compounds and pharmacological preparations including them | |
| PL2124556T3 (pl) | Kompozycje farmaceutyczne | |
| HUE038953T2 (hu) | Peptid szekvenciák és készítmények anopheles gambiae-fajból | |
| IL206594A (en) | The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations | |
| PL2154966T3 (pl) | Benzoimidazole i ich kompozycje farmaceutyczne | |
| IL193211A (en) | Derivatives of Indzol-Troaril and pharmaceutical preparations containing them | |
| GB0617191D0 (en) | Improvements in pharmaceutical compositions | |
| EP2109454A4 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1 | |
| PL2236145T3 (pl) | Kompozycja farmaceutyczna i lek złożony | |
| GB0614365D0 (en) | Pharmaceutical compositions and their use | |
| IL194844A0 (en) | New synergistic pharmaceutical composition | |
| ZA200904725B (en) | GLP-1 Pharmaceutical compositions | |
| GB0614848D0 (en) | Improvements in pharmaceutical compositions | |
| IL178937A0 (en) | Pharmaceutical and cosmetic compositions | |
| HU0700096D0 (en) | Homeopathic pharmaceutical compositions |